MIF is elevated in multiple hematologic malignancies, including lymphoma, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), and ALL, where it is correlated with adverse outcomes [74,86,111,112,113,114,115]. This evidence concerns the gene MIF and acute myeloid leukemia.